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Antibiotic fixed dose combinations (FDCs) can have clinical advantages such as improving
effectiveness and adherence to therapy. However, high use of potentially inappropriate
FDCs has been reported, with implications for antimicrobial resistance (AMR) and toxicity.
We used a pharmaceutical database, IQVIA-Multinational Integrated Data Analysis System
(IQVIA-MIDAS®), to estimate sales of antibiotic FDCs from 75 countries in 2015. Antibiotic
consumption was estimated using standard units (SU), defined by IQVIA as a single tablet,
capsule, ampoule, vial or 5ml oral suspension. For each FDC antibiotic, the approval status
was assessed by either registration with the United States Food and Drug Administration
(US FDA) or inclusion on the World Health Organization (WHO) Essential Medicines List
(EML). A total of 119 antibiotic FDCs were identified, contributing 16.7 x 109 SU, equalling
22% of total antibiotic consumption in 2015. The most sold antibiotic FDCs were amoxicillin-
clavulanic acid followed by trimethoprim/sulfamethoxazole and ampicillin/cloxacillin. The
category with the highest consumption volume was aminopenicillin/β-lactamase inhibitor +/-
other agents. The majority of antibiotic FDCs (92%; 110/119) were not approved by the US
FDA. Of these, the most sold were ampicillin/cloxacillin, cefixime/ofloxacin and metronida-
zole/spiramycin. More than 80% (98/119) of FDC antibiotics were not compatible with the
2017 WHO EML. The countries with the highest numbers of FDC antibiotics were India (80/
119), China (25/119) and Vietnam (19/119). There is high consumption of FDC antibiotics
globally, particularly in middle-income countries. The majority of FDC antibiotic were not
approved by either US FDA or WHO EML. International initiatives such as clear guidance
from the WHO EML on which FDCs are not appropriate may help to regulate the
manufacturing and sales of these antibiotics.
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Introduction
Global antibiotic consumption has been changing rapidly, increasing by 65% between 2000
and 2015, mainly in low- and middle-income countries (LMICs) [1,2]. Fixed dose combina-
tions (FDCs) including one or more products with antibacterial activity have previously been
noted as a concern, but there has been limited data on the scale of their use [3–6]. FDCs are
defined by the World Health Organization (WHO) as “A combination of two or more actives in
a fixed ratio of doses. This term is used generically to mean a particular combination of actives
irrespective of the formulation or brand. It may be administered as single entity products given
concurrently or as a finished pharmaceutical product” [7]. These products can have advantages
such as improving treatment response compared to monotherapy, due to synergistic mecha-
nisms (such as sulfamethoxazole/trimethoprim), or by increasing adherence to therapy.
FDCs are well-established in conditions such as tuberculosis, malaria and HIV treatment.
However, the consumption of potentially clinically inappropriate antibiotic FDCs has been
reported in some countries, raising concerns about the lack of proven efficacy, increasing tox-
icity or their potential effect on selecting for antimicrobial resistance (AMR) [4–6]. In 2017,
the WHO Essential Medicines List (EML) Working Group classified antibiotics in the EML
and EML for Children (EMLc) into three groups: Access, Watch, and Reserve (AWaRe classifi-
cation). The Access group contains generally narrow spectrum antibiotics recommended as
first and second choice for most common clinical infection syndromes. The Watch group con-
tains broader spectrum antibiotic classes corresponding to the highest priority agents on the
list of critically important antimicrobial drugs for human medicine. The Reserve group con-
sists of last resort antibiotics for targeted use in multidrug resistant infections (Sharland et al.,
2018). The new AWaRe classification is intended to be easy to apply to monitor antibiotic use
and inform antibiotic stewardship. We therefore aimed to quantify the global consumption of
antibiotic FDCs and to describe the types of combinations used. We also identified their
approval status with the US Food and Drug Administration (FDA) and compatibility with the
WHO’s 2017 revision of the Essential Medicines List (EML).
Methods
Data
This was an ecological study to assess the total sale of antibiotic FDCs. We estimated global
antibiotic FDCs sales in 2015 using the IQVIA-Multinational Integrated Data Analysis System
(IQVIA-MIDAS1) database. IQVIA-MIDAS is a commercial database containing data from
pharmacy retails sales throughout the supply chains, including overall antibiotic volume sold
to retailers and hospital pharmacies by wholesalers. The proportion of wholesalers contribut-
ing data to IQVIA-MIDAS varies between represented countries and IQVIA adjusts the
reported data based on the market share of participating wholesalers, to provide estimates of
total sales in the sectors represented in each country. Our dataset contains annual pharmaceu-
tical sales data for 75 countries/regions. Central America (Costa Rica, El Salvador, Guatemala,
Honduras, Nicaragua, and Panama) and Francophone West Africa (Benin, Burkina Faso,
Cameroon, Chad, Côte d’Ivoire, Republic of Congo, Guinea, Mali, Niger, Senegal, and Togo)
are defined as two regions with aggregated sales for these countries in the database [8].
Annual sales of each antibiotic (including information on component antibiotics, formula-
tion, trade name and manufacturer) are recorded for each country. Antibiotic sales were
expressed in standard units (SU), with 1 SU defined by IQVIA as one tablet, capsule or
ampoule/vial or 5ml oral suspension. We did not include anti-tuberculosis drugs, antiviral
drugs, and antifungal drugs in our analyses.
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Analysis
We defined antibiotic FDCs as medications consisting of at least one Anatomical Therapeutic
Chemical (ATC) code J01 systemic antibiotic with another J01 antibiotic or a β-lactamase
inhibitor or a 5-nitroimidazole with or without any other medication (e.g probiotics, non-ste-
roidal anti-inflammatory drugs). Antibiotic FDCs were aggregated in categories based on the
WHO ATC Classification System [9]. Penicillins were classified as β-lactamase sensitive peni-
cillins, β-lactamase resistant penicillins, aminopenicillins, ureidopenicillins and carboxypeni-
cillins. Ureidopenicillins and carboxypenicillin were grouped as antipseudomonal penicillins
[10]. The total annual sales of each antibiotic FDC sold was recorded by formulation type. For
each antibiotic FDC, we summed the total consumption and reported the number of countries
where it was sold. Total consumption for each antibiotic FDC was quantified by country
income. The World Bank categories were used to classify countries as high income and low/
middle income countries (HICs and LMICs) [11].
Approval status of antibiotic FDCs. Each of the antibiotic FDCs was categorised as
approved or not approved by the US FDA by searching the FDA website [12]. For each coun-
try, the number and volume of antibiotic FDCs not approved by the FDA was expressed as a
percentage of total antibiotic sales and total antibiotic FDCs.
Classification of antibiotic FDCs according to WHO criteria. Antibiotic FDCs were
also assessed based on the WHO 2017 revision of EML [13]. EML compatible antibiotic FDCs
were grouped into Access, Watch, and Reserve using the WHO AWaRe classification.
Antibiotic FDCs with two critically important antibiotics. The components of the anti-
biotic FDCs were also matched to the WHO’s “critically important antibiotics” (CIA) classifi-
cation [14] to identify antibiotic FDCs in which both the components belonged to the “highest
priority critically important antibiotics” group.
Results
A total of 74.4 x 109 SU of antibiotic agents was sold in 2015. Amongst these, 119 different anti-
biotic FDCs were identified (S1 Table), contributing to 16.7 x 109 SU, 22.5% of all antibiotic
sales. The highest number of antibiotic FDCs were in the category of aminopenicillin/β-lacta-
mase resistant penicillin (Table 1). The category with the greatest sales was that of aminopeni-
cillin /β-lactamase inhibitor +/- other agents (Table 1).
Approximately one in six (20/119) antibiotic FDCs included probiotics as additional agents;
probiotics were mostly Lactobacillus acidophilus and Bacillus coagulans. The most sold was
cefixime/dicloxacillin/Lactobacillus acidophilus. The country with the highest number of anti-
biotic FDCs sold was India (80), followed by China (25) and Vietnam (19) (Fig 1). Overall, the
most sold FDC by volume was amoxicillin/clavulanic acid (8.38 x 109 SU), followed by sulfa-
methoxazole/trimethoprim (3.61 x 109 SU) and ampicillin/cloxacillin (0.95 x 109 SU) (Table 2
and S1 Table). Amoxicillin/clavulanate and sulfamethoxazole/trimethoprim were sold by all
75 countries; other widely sold antibiotic FDCs were piperacillin/tazobactam (66) and ampicil-
lin/sulbactam (49) (Table 2).
Compared to other countries, India accounted for the greatest sales volume of amoxicillin/
clavulanic acid, sulfamethoxazole/trimethoprim, and ampicillin/cloxacillin. There were clear
country level differences in sales of FDCs, with the highest sales of piperacillin/tazobactam in
Australia, metronidazole/spiramycin in France and cefoperazone/sulbactam in China.
FDA approval
Only 9/119 antibiotic FDCs were approved by the US FDA (7.5%) (Table 3). Of the 110 antibi-
otic FDCs not authorized by US FDA (92.5%), the highest numbers of combinations and the
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largest sales volumes were in the categories containing aminopenicillin+β-lactamase resistant
penicillins +/- other agents (probiotics, lactic acid, serrapeptase) (19) and that including 3rd-
4th-5th generation cephalosporins/β-lactamase resistant penicillins +/- other agents (13) (S2
Table).
Overall, 53/75 (70.7%) countries sold at least one FDC not approved by the US FDA (Fig 1);
31/53 countries (58.4%) were LMIC. The highest number of “not FDA-approved” antibiotic
FDCs were sold in India, China, Francophone West Africa and Vietnam (Fig 1). India and
Francophone West Africa had the highest percentage of antibiotic FDCs not approved by the
US FDA (93.8% of total antibiotic FDCs). Ampicillin/cloxacillin was the highest sold antibiotic
FDC which was not FDA-approved, followed by cefixime/ofloxacin, and metronidazole/spira-
mycin (Table 4). A total of 3.81 x 109 SU of antibiotic FDCs not approved by the US FDA were
sold, corresponding to 22.7% of the antibiotic FDCs SU sold and to 5.1% of the total antibiotic
consumption, with considerable variation across countries (S3 Table).
Table 1. Categories of antibiotic Fixed Dose Combinations (FDCs).
FDC types Standard Unite sold Number of FDCs
Aminopenicillin /β-lactamase inhibitor //- other agents 8.60 x 109 8
Sulphonamides/trimethoprim+/- other agents 3.62 x 109 9
Aminopenicillin / β-lactamase resistant penicillin +/- other agents 1.54 x 109 21
Antipseudomonal penicillin /β-lactamase inhibitor 0.95 x 109 4
3rd-4th-5th gen. cephalosporins /β-lactamase inhibitor +/- other agents 0.55 x 109 15
Cephalosporins / fluoroquinolones 0.40 x 109 6
1st-2nd gen. cephalosporins / β-lactamase inhibitor +/- other agents 0.26 x 109 8
Macrolide/ 5-nitroimidazole 0.24 x 109 3
Macrolide/cephalosporin+/-other agents 0.21 x 109 3
Cephalosporin/ β-lactamase resistant penicillin +/- other agents 0.10 x 109 7
Cephalosporin/trimethoprim 0.09 x 109 2
Cephalosporin/oxazolidinone 0.04 x 109 2
Fluoroquinolone/ 5-nitroimidazole 0.04 x 109 8
Macrolide / fluoroquinolone +/- other agents 0.04 x 109 2
Cephalosporin/5-nitroimidazole 0.03 x 109 1
Other combinations 0.01 x 109 20
https://doi.org/10.1371/journal.pone.0241899.t001
Fig 1. Number of fixed dose combination (FDC) antibiotic sold by country.
https://doi.org/10.1371/journal.pone.0241899.g001
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Compatibility of antibiotic FDCs with the WHO EML
Among the 119 antibiotic FDCs, 98 (82.3%) were not compatible with the 2017 WHO EML
(S4 Table). Among the 21 WHO-compatible antibiotic FDCs (S3 Table), 2 belonged to the
“Access” category (amoxicillin/clavulanic acid and sulfamethoxazole/trimethoprim), 16 were
compatible with the “Watch” group and 3 with the “Reserve” group (S4 Table). Ten antibiotic
FDCs included two highest priority critically important antibiotics (S5 Table). Of these, the
largest consumption volumes were reported for cefixime/ofloxacin and azithromycin/cefix-
ime; none of these 10 antibiotic FDCs were listed on the EML or approved by the US FDA.
Discussion
We have analysed sales data on antibiotic fixed dose combinations from 75 countries, adding
to previous studies which used data from single countries or regions [4–6]. Overall, antibiotic
FDCs represent a substantial proportion of all systemic antibiotic consumption, accounting
for about 20% of systemic antibiotic SU sold in 2015. The majority of the antibiotic FDCs iden-
tified were not compatible with the EML and were not approved by the US FDA, and several
antibiotic FDCs contained two agents classified by the WHO as highest priority critically
important antibiotics.
Globally, the most sold antibiotic FDCs were amoxicillin/clavulanate and sulfamethoxa-
zole/trimethoprim, which were sold in all countries and accounted for about 50% and 20% of
the total antibiotic FDCs consumption, respectively. This is consistent with these drugs being
recommended for treatment of common infectious conditions (such as acute otitis media,
community acquired pneumonia and urinary tract infections) and with their inclusion on the
Table 2. Top 10 list of most sold antibiotic FDCs and the number of countries they are sold in.
FDC Standard Unite sold Number of countries sold in
amoxicillin/clavulanic acid 8.38 x 109 75
sulfamethoxazole/trimethoprim 3.61 x 109 75
ampicillin/cloxacillin 0.95 x 109 13
piperacillin/tazobactam 0.79 x 109 66
cefixime/ofloxacin 0.31 x 109 1
metronidazole/spiramycin 0.24 x 109 17
cefpodoxime proxetil/clavulanic acid 0.23 x 109 3
amoxicillin/flucloxacillin 0.19 x 109 7
azithromycin/cefixime 0.17 x 109 2
cefoperazone/sulbactam 0.16 x 109 28
https://doi.org/10.1371/journal.pone.0241899.t002
Table 3. Antibiotic FDCs authorized by FDA and the number of countries they are sold in.
FDCs Standard Unite sold globally Number of countries sold in
amoxicillin/clavulanic acid 8.38 x 109 75
sulfamethoxazole/trimethoprim 3.61 x 109 75
piperacillin/tazobactam 0.79 x 109 66
ampicillin/sulbactam 0.12 x 109 49
clavulanic acid/ticarcillin 0.02 x 109 19
phenazopyridine/sulfamethoxazole/trimethoprim 0.02 x 108 1
ceftolozane/tazobactam 0.01 x 107 9
avibactam/ceftazidime 0.07 x 106 2
dalfopristin/quinupristin 0.02 x 106 3
https://doi.org/10.1371/journal.pone.0241899.t003
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EML as Access antibiotics [13]. However, there were many other widely used antibiotic FDCs,
particularly from middle income countries, that were not on the EML. The category including
the highest number of types of antibiotic FDCs was that of aminopenicillin/ β-lactamase resis-
tant penicillins with or without probiotics followed by 3rd-4th-5th generation cephalosporins
plus β-lactamase inhibitors with or without probiotics.
Defining clinically “inappropriate” antibiotic FDCs is complex and beyond the scope of this
study. Previous studies have used as a standard of appropriateness the authorization status of
antibiotic FDCs by the FDA, UK Medicines and Healthcare products Regulatory Agency
(MHRA) and European Medicines Agency (EMA) and local drug regulatory organisations [4–
6]. We only used the US FDA to evaluate approval status for marketed FDC antibiotics in this
study, as US FDA regulation is a widely accepted benchmark for drug approvals globally, while
the EMA has both centralised and devolved local regulations for drug approval processes.
However, countries with different health priorities to the US may investigate and approve
drugs (including antibiotic FDCs) which have not been approved by the US FDA. Therefore,
in some countries, the use of antibiotic FDCs not approved by the US FDA might be clinically
appropriate (e.g. those including aminopenicillin/β-lactamase inhibitor, anti-pseudomonas
penicillin / β-lactamase inhibitor or a third-fourth-fifth generation cephalosporins/β-lactamase
inhibitor and the wider group of sulphonamides/trimethoprim) [15]. Some of these antibiotic
FDCs are part of the Watch and Reserve groups of the EML [13], therefore their consumption
should be further monitored, investigated and potentially limited to selected indications.
On the other hand, for other combinations there appears to be no potential clinical addi-
tional benefit compared to the individual drugs formulated alone, such as those including two
drugs belonging to the same class (cefpodoxime proxetile/cefixime, ampicillin/sultamicillin).
There is limited evidence supporting the use of the three antibiotic FDCs accounting for the
greatest consumption (ampicillin/cloxacillin, cefixime/ofloxacin and metronidazole/spiramy-
cin). The clinical utility of using ampicillin/cloxacillin has been questioned [16–18], as the two
antibiotics have overlapping spectra of activity and medical indications that require both these
antibiotics as an empiric therapy are not common [16]. Cefixime/ofloxacin was only sold in
India where the oral formulation was approved in 2010 for treating typhoid fever [19] in
response to the increasing prevalence of Salmonella typhi resistant to quinolones [20]. Two
randomized clinical trials are ongoing to compare cefixime/ofloxacin to ofloxacin for the ther-
apy of typhoid fever, and may provide evidence about clinical effectiveness and safety of this
combination [21,22]. Metronidazole/spiramycin (indicated for treatment of periodontitis)
[23] was sold mainly in France and Vietnam. It has been reported that these two antibiotics
Table 4. Antibiotic FDCs sold in the highest volumes in 2015 and not FDA approved FDCs and number of coun-
tries sold in.
FDC Standard Unite globally sold Number of countries sold in
ampicillin/cloxacillin 0.95 x 109 13
cefixime/ofloxacin 0.31 x 109 1
metronidazole/spiramycin 0.24 x 109 17
cefpodoxime proxetil/clavulanic acid 0.22 x 109 3
amoxicillin/flucloxacillin 0.19 x 109 7
azithromycin/cefixime 0.17 x 109 2
cefoperazone/sulbactam 0.16 x 109 28
amoxicillin/cloxacillin 0.16 x 109 4
cefixime/clavulanic acid 0.12 x 109 2
cefalexin/trimethoprim 0.09 x 109 1
https://doi.org/10.1371/journal.pone.0241899.t004
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have shown synergism in vitro against oral cavity bacteria and their efficacy was similar to
amoxicillin-clavulanate but also to metronidazole monotherapy [24]. For this reason, it has
been recommended in patients with history of hypersensitivity to amoxicillin/clavulanate.
Concerns regarding clinical efficacy
The approval of antibiotic FDCs may not always require evidence of efficacy and toxicity [7].
Evidence of clinical efficacy and safety of the single components or studies on the combination
of the two agents can be sufficient, even if not in a fixed dose ratio [7]. A review of 22 different
Indian brands of FDCs containing azithromycin with ofloxacin or cefixime reported that
while the formulations contained an adequate dose of fluoroquinolone or cephalosporin, the
dose of azithromycin was only 250 mg/tablet (one fifth of the WHO-recommended dose for a
60 kg individual (1200 mg; 10 mg/kg per day)) [25]. In India, dosing of ceftriaxone/vancomy-
cin is recommended twice a day [26]. This dosing frequency is widely accepted for ceftriaxone
[27] but administration of vancomycin is usually recommended every 6–8 hours [28].
Concerns regarding safety
There are limited data comparing toxicity resulting from antibiotic FDCs versus monotherapy
for conditions other than tuberculosis. However, antibiotic FDCs (particularly those classified
as irrational based on the 2012 WHO Essential Drug Model list) have been associated with
about 20% of the total adverse drug reactions as a result of antibiotics (26). The combination
most commonly associated with adverse events was Ofloxacin/Ornidazole, in terms of cutane-
ous manifestations [29]. Moreover, some antibiotic FDCs not approved by the FDA include
narrow therapeutic index antibiotics such as glycopeptides and aminoglycosides (ceftriaxone/
vancomycin, amikacin/cefepime).
Concerns regarding AMR
Gautam et al suggested a possible role of the injudicious use of antibiotic FDCs in the emer-
gence of ciprofloxacin-resistant Salmonella typhi strains in India [30]. However, this is a com-
plex area as the development of antibiotic FDCs may in part be a response to high AMR rates
(as with the licensing in India of cefixime/ofloxacin for typhoid fever) [31,32]. Antibiotic
FDCs may contribute to AMR by exposing bacteria to sub-therapeutic concentrations of one
or both antibiotic components since sub-therapeutic concentrations can exert non-lethal selec-
tive pressures [31]. This selection of resistant strains may further contribute to a reduction in
clinical effectiveness.
Country specific FDC antibiotic use
Antibiotic FDCs not approved by the US FDA were most commonly sold in middle-income
countries, particularly in India, where the sale of US FDA unapproved FDCs accounts for
around 50% of antibiotic FDCs and about 16% of overall antibiotics, considerably higher than
many other countries. These differences between countries in terms of number and consump-
tion of antibiotic FDCs not approved by the US FDA can be related to several factors, includ-
ing differences in government regulation [6]. For example, in India, many antibiotic FDCs
have historically been sold without authorisation from the Central Drugs Standard Control
Organisation (CDSCO), the national regulator [33]. Since 2014/5, the CDSCO has been pro-
viding reports of the rationality of FDCs, thus leading the government to ban their manufac-
ture, sale and distribution [4,34]. Among these products, several antibiotics FDCs are listed
[35,36].
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The many factors which contribute to national differences in consumption of antibiotic FDCs
include different prevalence of infectious diseases, access to medical facilities and appropriate
diagnostic procedures, accessibility of essential drugs [17], inappropriate prescribing practices
[37] and over the counter and non-prescription supply of antimicrobials [1]. Contributing factors
for non-prescription antimicrobial supply are poor national medicines regulations, limited avail-
ability of qualified pharmacists and commercial pressure on pharmacy staff, consumer demand
and lack of awareness of AMR [38]. Two recent studies in China and Vietnam have shown that
patients were able to purchase non-prescription antibiotics through various sources (e.g. online
pharmacy, illegal drug suppliers) [39,40]. The rationale for individuals using and healthcare
workers providing FDC antibiotics should be further explored. Studies are also required to better
evaluate their efficacy, effectiveness, safety and potential to accelerate the development of AMR.
Strengths and limitations
To our knowledge, this is the first comprehensive study to assess FDC antibiotic sales at the
global level. However, several limitations need to be addressed. The IQVIA database contains
aggregate, country-level data without information about indications of therapy, consumers’
age, or setting (hospital, community). The sales data were not adjusted for population size,
which partly explains the apparently large contribution of highly populated countries such as
India. The IQVIA database is not globally representative (for example, only two low income
countries contribute data; these are both part of Francophone West Africa); however, it does
provide valuable information on the scale of antibiotic use in the included countries [8]. The
IQVIA company estimates coverage for each country internally and applies correction factors
to estimate total sales in the sectors covered in each country. Data are also validated against
alternative data sources [41]. Despite this uncertainty about the precise volume of FDC antibi-
otics sold and the validity of comparisons between countries, our analyses support the conclu-
sion that antibiotic FDCs are sold in large volumes in many countries. Finally, it is not possible
to distinguish sales of prescription and non-prescription antibiotics in this database.
As discussed above, US FDA authorization cannot be considered as the gold standard mea-
sure of a drug’s appropriateness. We use this for illustrative purposes and not to formally assess
the appropriateness of particular antibiotic FDCs in a given context; we acknowledge that indi-
vidual countries may have valid reasons to approve antibiotic FDCs not approved (or not
assessed) by the US FDA.
Conclusions
A high consumption of FDC antibiotic globally was observed, particularly in middle-income
countries. Antibiotic FDCs account for a substantial proportion of antibiotic consumption
and some of these FDCs may not be clinically appropriate, depending on the context. Consid-
ering the reported concerns in terms of efficacy, toxicity and AMR, the rationale for using anti-
biotic FDCs should be explored further and where required studies conducted to assess their
effectiveness, safety and potential to accelerate the development of AMR. International initia-
tives may be needed to regulate the manufacturing and sale of these medications while main-
taining access to essential antibiotics, with particular attention to LMICs. Central guidance
from the WHO EML could be helpful to assist in determining the clearly inappropriate FDCs
and discouraging their manufacture and sale.
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